- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05001009
Goals of Care Conversations Study (LSTDI)
Improving Implementation of Outpatient Goals of Care Conversations for Veterans With Serious Illness
Study Overview
Status
Conditions
Detailed Description
The aims of this study are as follows:
Aim 1. Use a clinician-level SMART in three VA health systems to determine the effectiveness of clinician and patient implementation strategies to improve the occurrence of documented goals of care conversations in Veterans with serious medical illness. Hypothesis 1 (first stage of the SMART): Compared to a low intensity clinician strategy alone, a low intensity clinician and patient strategy will lead to increased documentation of goals of care conversations. Hypothesis 2. Among those who do not respond to low intensity strategies, compared to a high intensity clinician strategy paired with a low intensity patient strategy, a high intensity clinician and patient strategy will lead to increased documentation of goals of care conversations.
Aim 2a. Identify the sequence of implementation strategies that leads to the overall greatest increase in documentation of goals of care conversations. Aim 2b (exploratory). Identify patient and clinician characteristics that modify the effect of sequences of implementation strategies on documentation of goals of care conversations.
Aim 3. Understand clinician and patient implementation strategy success or failure using a mixed method evaluation involving clinicians, leaders, patients, and caregivers.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304-1207
- VA Palo Alto Health Care System, Palo Alto, CA
-
West Los Angeles, California, United States, 90073-1003
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA
-
-
Colorado
-
Aurora, Colorado, United States, 80045-7211
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
CLINICIANS VA primary care advance practice clinicians (MDs, APRNs, PAs) at one of the three study sites able to complete goals of care conversation notes and orders. Advance practice clinicians will be eligible for randomization if they have at least 15 eligible patients without goals of care conversation notes at the start of stage 1 (to allow participating clinicians ample opportunities to write notes) and have written fewer than 4 goals of care conversation notes in the previous 6 months (to select clinicians who need improvement), and can potentially receive the planned implementation strategies, i.e., clinicians who regularly attend the Patient Aligned Care Team (PACT) team meetings.
PATIENTS
- Veteran enrolled in VHA health care in one of the three study sites who is a current patient of one of the eligible primary care clinicians
- Diagnosis of cancer, heart failure, interstitial lung disease, chronic obstructive pulmonary disease, end-stage renal disease, end-stage liver disease, and dementia
- Care Assessment Need score of > or equal to 90 using the one-year combined hospitalization/mortality variable
Exclusion Criteria:
PATIENTS
- Prisoner
- Pregnant
- under 18 years of age.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: No then high patient engagement
First stage: No patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training. Second stage (non-responders only): High patient engagement and high intensity clinician training. |
Patients will be sent information about goals of care conversations, including the PREPARE website.
Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
Other Names:
A "booster" of the established LSTDI implementation strategy.
Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study.
Online training options and when and how to complete goals of care conversations and documentation will be highlighted.
This includes two components:
|
|
Active Comparator: No then low patient engagement
First stage: No patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training. Second stage (non-responders only): Low intensity patient engagement and high intensity clinician training. |
Patients will be sent information about goals of care conversations, including the PREPARE website.
Other Names:
A "booster" of the established LSTDI implementation strategy.
Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study.
Online training options and when and how to complete goals of care conversations and documentation will be highlighted.
This includes two components:
|
|
Active Comparator: Low then high patient engagement
First stage: Low intensity patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training. Second stage (non-responders only): High patient engagement and high intensity clinician training. |
Patients will be sent information about goals of care conversations, including the PREPARE website.
Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
Other Names:
Patients will be sent information about goals of care conversations, including the PREPARE website.
Other Names:
A "booster" of the established LSTDI implementation strategy.
Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study.
Online training options and when and how to complete goals of care conversations and documentation will be highlighted.
This includes two components:
|
|
Active Comparator: Low then low patient engagement
First stage: Low patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training. Second stage (non-responders only): Low intensity patient engagement and high intensity clinician training. |
Patients will be sent information about goals of care conversations, including the PREPARE website.
Other Names:
A "booster" of the established LSTDI implementation strategy.
Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study.
Online training options and when and how to complete goals of care conversations and documentation will be highlighted.
This includes two components:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of patients with a goals of care conversation note documented in Stage 2
Time Frame: From the start of stage 2 to 9 months later
|
Amongst patients attributed to a clinician who was randomized in Stage 2, whether or not a goals of care conversation note was written during Stage 2.
|
From the start of stage 2 to 9 months later
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of patients with a goals of care conversation note documented in Stage 1 or 2
Time Frame: From the start of stage 1 to 9 months after the start of stage 2
|
Amongst all patients in the study, whether or not a goals of care conversation note was written during the study.
|
From the start of stage 1 to 9 months after the start of stage 2
|
|
Percent of patients with a goals of care conversation note documented in Stage 1
Time Frame: From the start of stage 1 to the beginning of stage 2 (approximately 8 months)
|
Amongst all patients in the study, whether or not a goals of care conversation note was written during stage 1
|
From the start of stage 1 to the beginning of stage 2 (approximately 8 months)
|
Collaborators and Investigators
Investigators
- Principal Investigator: David Bekelman, MD MPH, Rocky Mountain Regional VA Medical Center, Aurora, CO
- Principal Investigator: Anne M Walling, MD PhD, VA Greater Los Angeles Healthcare System, West Los Angeles, CA
Publications and helpful links
General Publications
- Ha DM, Deng LR, Lange AV, Swigris JJ, Bekelman DB. Reliability, Validity, and Responsiveness of the DEG, a Three-Item Dyspnea Measure. J Gen Intern Med. 2022 Aug;37(10):2541-2547. doi: 10.1007/s11606-021-07307-1. Epub 2022 Jan 3.
- Haverfield MC, Ma J, Walling A, Bekelman DB, Brown-Johnson C, Lo N, Lorenz KA, Giannitrapani KF. Communication processes in an advance care planning initiative: A socio-ecological perspective for service evaluation. Palliat Med. 2024 Dec;38(10):1134-1143. doi: 10.1177/02692163241277394. Epub 2024 Sep 10.
- Bekelman DB, Giannitrapani K, Linn KA, Langner P, Sudore RL, Rabin B, Lorenz KA, Foglia M, Glickman A, Pawlikowski S, Sloan M, Gamboa RC, McCaa MD, Hines A, Walling AM. Increasing goals of care conversations in primary care: Study protocol for a cluster randomized, pragmatic, sequential multiple assignment randomized trial. Contemp Clin Trials. 2024 Oct;145:107643. doi: 10.1016/j.cct.2024.107643. Epub 2024 Jul 27.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Respiratory Tract Diseases
- Digestive System Diseases
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Liver Failure
- Hepatic Insufficiency
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Liver Diseases
- Lung Diseases, Interstitial
- Kidney Failure, Chronic
- End Stage Liver Disease
Other Study ID Numbers
- IIR 19-018
- HX002935 (Other Identifier: eRA Project Ref)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
University of Health Sciences LahoreRecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, SystolicPakistan
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Lakeland Regional Health Systems, Inc.RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IVUnited States
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Eli Lilly and CompanyNot yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, SystolicUnited States, Japan
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
Clinical Trials on High patient engagement
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
University of VermontPatient Engagement Systems; Empire Physicians Medical GroupTerminated
-
Northwestern UniversityNational Cancer Institute (NCI); Northwestern MedicineCompleted
-
Sheba Medical CenterCompletedGastric Cancer | Esophageal Cancer | Small Bowel Cancer | Rectal Cancer | Cholangiocarcinoma | Colon Cancer | Pancreas CancerIsrael
-
Thomas Jefferson UniversityHeart and Diabetes Center North Rhine-Westphalia; Inova Fairfax Hospital; Resmed... and other collaboratorsTerminatedHeart Failure | Sleep Disorder; Breathing-RelatedUnited States, Germany
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingUrinary Incontinence | Overactive Bladder SyndromeUnited States
-
Kowloon Hospital, Hong KongUnknown
-
University of PittsburghCompleted
-
The University of Texas at DallasNational Institute on Aging (NIA); University of Texas Southwestern Medical... and other collaboratorsTerminatedCognitive ChangeUnited States